Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$3.8B
71M shares
52-week range
$18.26 β $94.90
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
www.structuretx.comNo one on the platform currently holds GPCR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 55,800 | $2.7M |
No one on the platform has traded GPCR yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$GPCR $VKTX BL has to be shorting his own company π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π€‘π©Έ
View on StockTwits β$VKTX wonder who has the BIC drug ππππππ meanwhile not a single drug on the market and Dr.Lian has cashed $76,000,000 in options over the yearsπ€‘π€‘π€‘π€‘ keep buying guys! $GPCR now with a higher mcap than Viking. Trading like they are tapping the ATM!
View on StockTwits β$VKTX $GPCR one at high of day one at low of day. take a guess
View on StockTwits β$GPCR $VKTX Look forward to the September episode, where this idiot draws even more boobs and penises with his colored pencils on charts and talks about the stock dropping from $70 because his fridge drawings for his mom tell him so.
View on StockTwits βGOT THIS IDEA FROM CNBC ON TV 175.00 !N PROF!T ! So easy, even a caveman can do it. $GPCR
View on StockTwits β$GPCR looks like I'm chasing it b just now 8/12 1:15 pm edt 08/12/2026 Buy GPCR STRUCTURE THERAPEUTICS FUNSPONSORED ADR 1 ADR REPS 3 ORD SHS 25 $52.00 -$1,300.00 More 08/06/2026 Sell GPCR STRUCTURE THERAPEUTICS FUNSPONSORED ADR 1 ADR REPS 3 ORD SHS 25 $51.57 $0.03 $1,289.22 More 07/27/2026 Buy GPCR STRUCTURE THERAPEUTICS FUNSPONSORED ADR 1 ADR REPS 3 ORD SHS 25 $49.37 -$1,234.25
View on StockTwits β$GPCR dug out some info maybe useful in general so resharing instead of replying π. On August 6, GPCR announced that it had started dosing patients in its Phase 3 ACCOMPLISH program for aleniglipron. Management also explicitly laid out the upcoming catalyst calendar: * Q3 2026: 72-week ACCESS OLE data * Q3 2026: initial ACCG-2671 amylin data * Q4 2026: body-composition data * Q4 2026: obesity/T2D data * Q4 2026: SWITCH study β patients moving from injectable GLP-1s to oral aleniglipron * Q4 2026: initiation of the GLP-1 + amylin combination trial.
View on StockTwits β$GPCR what are they waiting for? Any big milestone before BO? Any thoughts?
View on StockTwits β$GPCR very high option call volume at $100 for Oct 16th 2026. It has been this way for at least 6 months, so may have just been a large position setup a long ways back, but it has also grown 20% or so the past couple weeks which is interesting. Thoughts?
View on StockTwits β$GPCR they are the belle of the ball. They will get 14B. Next year though .
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $42M | +95.2% | $-1.43 | $-1.69β$-1.26 | β | 10 |
| 2027 | $55556 | -99.9% | $-1.98 | $-2.52β$-1.71 | β | 9 |
| 2028 | $213M | +383355.0% | $-1.54 | $-2.33β$1.05 | β | 8 |
| 2029 | $539M | +153.2% | $-0.29 | $-0.29β$-0.29 | β | 5 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.39 | $-0.49 | -25.6% |
| 2026-05-07 | $-0.39 | $-0.35 | +10.3% |
| 2026-02-26 | $-0.35 | $-0.49 | -40.0% |
| 2025-11-06 | $-0.36 | $-0.37 | -2.8% |
| 2025-08-06 | $-0.28 | $-0.36 | -28.6% |
| 2025-05-08 | $-0.24 | $-0.27 | -12.5% |
| 2025-02-27 | $-0.23 | $-0.22 | +4.3% |
| 2024-11-13 | $-0.19 |
| $-0.20 |
| -5.3% |
| $1.8B |
| β |
| LQDALiquidia Corporation | $72.10 | -8.49% | $6.4B | β |
| MESOMesoblast Limited | $16.49 | -1.73% | $2.1B | β |
Source: Financial Modeling Prep Β· peers by sector/industry